- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06582368
Determinants of Portal Vein Pulsatility Index
August 31, 2024 updated by: Balan Ion Cosmin, Institutul de Urgenţă pentru Boli Cardiovasculare Prof.Dr. C.C. Iliescu
Determinants of Portal Vein Pulsatility Index: An Observational Study
The pulsatile pattern of the portal vein is considered a marker of right ventricular dysfunction, but volemia may also contribute to this phenomenon.
The separate influence of each factor remains debated, as the interplay between right ventricular dysfunction and volume status is complex.
Additionally, right ventricular dysfunction can originate from either diastolic or systolic dysfunction, further complicating the understanding of their distinct impacts on portal vein pulsatility.
Study Overview
Status
Completed
Conditions
Detailed Description
The pulsatile pattern of the portal vein has been recognized as a potential marker of right ventricular dysfunction, reflecting altered hemodynamics in the venous system.
However, the role of volemia, or the volume status of a patient, might also significantly influence this pulsatility, complicating the interpretation of portal vein flow patterns.
The distinct and combined effects of right ventricular dysfunction and volemia on portal vein pulsatility are still subjects of ongoing debate.
Right ventricular dysfunction itself can arise from multiple mechanisms, including primary diastolic dysfunction, where the ventricle has impaired filling and relaxation, or systolic dysfunction, characterized by reduced contractility and ejection capacity.
Understanding whether diastolic or systolic dysfunction plays a predominant role in altering portal vein pulsatility is crucial, as these nuances have important implications for accurately identifying the determinants of portal vein pulsatility index and tailoring appropriate clinical interventions.
Study Type
Observational
Enrollment (Actual)
60
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Bucharest, Romania, 022328
- "Prof CC Iliescu" Emergency Institue for Cardiovascular Diseases
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
No
Sampling Method
Non-Probability Sample
Study Population
Mechanically ventilated postoperative adult patients after cardiac surgery within 6 hours after intensive care unit admission.
Description
Inclusion Criteria:
- Informed consent.
- Mechanically ventilated patients within 6 hours after ICU admission following surgery who are considered for fluid administration to optimize haemodynamics.
- Sinus rhythm.
Exclusion Criteria:
- A condition known to interfere with portal vein flow assessment or interpretation (liver cirrhosis or chronic hepatic disease, suprahepatic or portal vein thrombosis).
- Any mechanical circulatory support.
- Cardiac transplant.
- Poor transthoracic echocardiographic window.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
|---|
|
Cardiac Surgery Patients
Mechanically ventilated postoperative adult patients after cardiac surgery within 6 hours after intensive care unit admission.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Fluid Intolerance
Time Frame: Within the first six hours of admission to the intensive care unit (simultaneously with other measures).
|
A portal vein pulsatility index greater than 50%, calculated as (Vmax - Vmin) / Vmax, with no upper limit and 0% as the minimum limit.
Higher values indicate worse outcomes.
Ultrasonographic portal spectral waveform was used to measure Vmax and Vmin.
|
Within the first six hours of admission to the intensive care unit (simultaneously with other measures).
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Volemia
Time Frame: Within the first six hours of admission to the intensive care unit (simultaneously with other measures).
|
Volemia will be assessed using the mean systemic filling pressure analogue (MSFPa), which estimates the overall volume status and preload of the circulatory system.
This measurement provides an indirect evaluation of volemia, reflecting the balance between blood volume and vascular capacity.
Higher or lower values can indicate fluid overload or deficit, respectively.
|
Within the first six hours of admission to the intensive care unit (simultaneously with other measures).
|
|
Right Ventricular Dysfunction
Time Frame: Within the first six hours of admission to the intensive care unit (simultaneously with other measures).
|
Right ventricular dysfunction will be assessed using three ancillary measures: Tricuspid Annular Plane Systolic Excursion (TAPSE), Right Ventricular Fractional Area Change (RVFAC), and the Right Ventricular End-Diastolic Area to Left Ventricular End-Diastolic Area ratio (RVEDA/LVEDA).
TAPSE measures longitudinal shortening of the right ventricle, RVFAC assesses overall systolic function by evaluating the change in the right ventricular area during the cardiac cycle, and RVEDA/LVEDA compares the size of the right ventricle to the left, indicating potential dilation or pressure overload.
|
Within the first six hours of admission to the intensive care unit (simultaneously with other measures).
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Investigators
- Study Director: Serban-Ion Bubenek-Turconi, Professor, "Prof CC Iliescu" Emergency Institue for Cardiovascular Diseases
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
May 1, 2023
Primary Completion (Actual)
July 1, 2024
Study Completion (Actual)
August 1, 2024
Study Registration Dates
First Submitted
August 30, 2024
First Submitted That Met QC Criteria
August 30, 2024
First Posted (Actual)
September 3, 2024
Study Record Updates
Last Update Posted (Actual)
September 4, 2024
Last Update Submitted That Met QC Criteria
August 31, 2024
Last Verified
August 1, 2024
More Information
Terms related to this study
Other Study ID Numbers
- 9593/04.04.2024
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Fluid Overload
-
Uppsala UniversityCompletedFluid Therapy | Fluid Overload | Critical CareSweden
-
Hospices Civils de LyonRecruiting
-
Nova Scotia Health AuthorityWithdrawnFluid OverloadCanada
-
All India Institute of Medical Sciences, RishikeshCompleted
-
Medical University of ViennaCompleted
-
Bakirkoy Dr. Sadi Konuk Research and Training HospitalCompleted
-
University of JordanCompleted
-
Nordsjaellands HospitalRigshospitalet, Denmark; University of CopenhagenRecruitingFluid Therapy | Fluid Overload | Fluid AccumulationSpain, Denmark, India, United Kingdom, Finland, Iceland, Lithuania, New Zealand, Norway, Sweden, Switzerland
-
Jagiellonian UniversityCompletedFluid Overload | Fluid LossPoland
-
Nuwellis, Inc.AKI Critical Care Research FoundationTerminatedFluid OverloadUnited States